About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 72834 record(s)
Req # A-2023-001606
The most recent Module 2.3: Quality Overall Summary (QOS) submitted the sponsor for the Semaglutide Abbreviated New Drug Submission (ANDS).Organization: Health Canada
September 2024
Req # A-2024-000043
All Instructions for Use (IFUs) for devices licensed under Medical Device License (MDL)106132 (RST DRUG OF ABUSE MULTI-TEST PANEL (URINE) II) and MDL105588 (RST DRUG OF ABUSE MULTI-TEST CUP (URINE) II) under Rapid Self Test Inc.Organization: Health Canada
September 2024
Req # A-2024-000126
In respect of the second, newest Abbreviated New Drug Submission (ANDS) for semaglutide (the Second Semaglutide ANDS), provide a copy of the ANDS cover letter of the company (sponsor) who submitted the Second Semaglutide ANDS.Organization: Health Canada
September 2024
Req # A-2024-000256
The labels for all package types for all strengths or combinations of strengths of the final dosage forms which were included in the initial filing of the Abbreviated New Drug Submission (ANDS) for Tolvaptan from which was accepted into review in…Organization: Health Canada
September 2024
Req # A-2024-000266
All correspondence and other records relating to any pre-submission meeting(s) requested by the sponsor of the Degarelix Abbreviated Drug Submission (ANDS), and any pre-submission inquir(y/ies) submitted by the sponsor of the Degarelix ANDS.Organization: Health Canada
September 2024
Req # A-2024-000307
Communications between Dr. Michael Couthart, head of the Creutzfeldt-Jakob Disease Surveillance System, and other senior provincial government officials about the mystery brain illness experienced in New Brunswick. Time-frame: Oct. 1, 2023, to Dec.…Organization: Health Canada
September 2024
Req # A-2024-000342
All Medical Device Incident Reports received by Health Canada pertaining to breast implants manufactured by Sientra/Clarion Medical Technologies and sold in Canada.Organization: Health Canada
September 2024
Req # A-2024-000362
Provide data on serious Adverse Drug Reaction (ADR) reporting by hospitals from January 1, 2023 to June 25, 2024.Organization: Health Canada
September 2024
Req # A-2024-000366
All emails and associated attachments corresponding to the leadup, request for, and ultimately deemed-unnecessary Issue Analysis Summary (IAS) that is referred to in the Inquiry of Ministry question number Q-2670 (2 May 2024) by Member of Parliament…Organization: Health Canada
September 2024
Req # A-2024-000436
Documents on the smoking prevalence of equity groups in Canada for calendar years 2018-2023.Organization: Health Canada
September 2024